StockData

HUTCHMED (China) vs Protagonist Therapeutics

HCM and PTGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HCM and PTGX compare

Protagonist Therapeutics grew revenue faster over the last twelve months (34.8% versus −13.0% for HUTCHMED (China)).

HUTCHMED (China) keeps more of each dollar of sales as profit, with a net margin of 83.3% compared with 29.4% at Protagonist Therapeutics.

Protagonist Therapeutics scores higher on the StockData Score (12 against 5 for HUTCHMED (China)), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHCMPTGX
Size and price
Market cap–$8.1B
Share price$14.40$124.67
Change, 1 year−4.5%47.3%
Change, 5 years−59.1%275%
Beta (5Y)0.750.59
Employees109132
StockData Score
Total score512 (better)
Valuation score00
Growth score02 (better)
Performance score34 (better)
Health score26 (better)
Dividend score00
Valuation
P/E–121×
P/S–28.6×
P/B–9.6×
EV/EBITDA–122×
P/FCF–61.8×
FCF yield–1.6%
Fair value–$41.72
Margin of safety–−199%
Growth
Revenue growth (TTM)−13.0%34.8% (better)
Revenue growth, 5Y average19.2% (better)10.0%
Net income growth (TTM)1111% (better)59.3%
EPS growth (TTM)1200% (better)47.1%
Profitability
Gross margin38.7%–
Operating margin−7.1%20.7% (better)
Net margin83.3% (better)29.4%
FCF margin−14.4%46.3% (better)
Return on equity36.7% (better)11.0%
Return on invested capital–73.3%
Financial health
Debt / equity0.09 (better)0.00
Interest coverage−13.7×–
Current ratio5.6421.71 (better)
Altman Z-score–111.10
Piotroski F-score45 (better)
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.51%117%
Held by insiders0.44%1.7%
Insider net buying, 12 months–−$95.0M
Superinvestors holding–1
Short interest, % of float–16.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.